IJR News — today's news from every side
open
serve
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Ask Genius
Apps
Ask Genius
Apps
Trending
Lilly Plans $2.88B Merida Autoimmune Acquisition
Business
— Sep 3, 2026
Eli Lilly is rapidly expanding beyond its obesity-and-diabetes blockbuster lineup, striking two multi-deal paths: a $2.875 billion-plus acquisition of Merida Biosciences to broaden its autoimmune and antibody-directed therapies, and a $3.83 billion spree to acquire three biotech firms—Curevo, LimmaTech Biologics, and Vaccine Company—to build a broader vaccine and infectious-disease pipeline. The moves underscore a strategy to diversify growth into immunology, infectious diseases, and autoantibody therapies while managing revenue risk from reliance on a small number of weight‑loss drugs.
+2
Share
GLP-1 drugs linked to heart risk worldwide
Health
— Aug 19, 2026
NBC Connecticut’s Beyond the Scale highlights that GLP-1 medications are being explored beyond weight loss, including potential benefits for fertility issues and endometriosis, with emphasis on medical oversight to prevent malnutrition and adverse effects. NGeneBio is developing genetic and blood tests to predict GLP-1 response and monitor pancreatic and biliary safety, while Buckle reports strong Q2 results amid growing interest in GLP-1 therapies, including prospects for oral formulations by 2030.
+4
Share
Nestlé Uses AI to Target GLP-1 Users
Health
— Aug 14, 2026
The rapid rise of GLP-1 weight‑loss drugs is reshaping the market as Nestlé leverages AI to turn potential threats into opportunities by developing nutrition products and addressing drug side effects, while major pharma players like Lilly and Novo Nordisk navigate revenue trajectories and competitive disputes. Across the industry, executives see GLP-1 therapies expanding beyond weight loss into broader health benefits, with AstraZeneca highlighting broader applications and regulators flagging safety and counterfeit risks as demand climbs.
+5
Share
Video
— YouTube
Jon on Trump's Meme Assault on Canada & the Alternate Reality He's Constructed | The Daily Show
The Daily Show · 8.6M views · Sep 9, 2026
21:06
Researchers Reveal 3D Genome Folding Linked to Alzheimer's Brain Changes
x/university-of-washington
— Jul 23, 2026
Multiple studies from CMU, Pitt, and UW connect Alzheimer's pathology to changes in the genome’s 3D architecture, linking genome folding to gene activity with advanced techniques like GAGE-seq and the Hicformer AI model to map these changes in brain tissue. Additional work highlights age-related genome regulation shifts, including microglial turnover and blood-brain barrier cell decline, alongside a mid-stage drug trial where an anti-tau therapy showed potential to slow cognitive decline, underscoring 3D genome remodeling as a core facet of disease and aging beyond amyloid and tau alone.
Share
IJR
State Treasurer Sounds Alarm About Americans’ Retirement Money ‘Lost In The Either’
Jack McGeever · 5 min · 3h
